KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Share-based Compensation: 2009-2024

Historic Share-based Compensation for Nektar Therapeutics (NKTR) over the last 16 years, with Dec 2024 value amounting to $21.6 million.

  • Nektar Therapeutics' Share-based Compensation fell 43.02% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year decrease of 36.59%. This contributed to the annual value of $21.6 million for FY2024, which is 35.27% down from last year.
  • As of FY2024, Nektar Therapeutics' Share-based Compensation stood at $21.6 million, which was down 35.27% from $33.4 million recorded in FY2023.
  • Nektar Therapeutics' Share-based Compensation's 5-year high stood at $94.7 million during FY2021, with a 5-year trough of $21.6 million in FY2024.
  • Its 3-year average for Share-based Compensation is $37.4 million, with a median of $33.4 million in 2023.
  • In the last 5 years, Nektar Therapeutics' Share-based Compensation grew by 0.44% in 2021 and then slumped by 41.75% in 2023.
  • Nektar Therapeutics' Share-based Compensation (Yearly) stood at $94.3 million in 2020, then increased by 0.44% to $94.7 million in 2021, then plummeted by 39.46% to $57.3 million in 2022, then tumbled by 41.75% to $33.4 million in 2023, then crashed by 35.27% to $21.6 million in 2024.